Update on postmenopausal osteoporosis management
نویسندگان
چکیده
منابع مشابه
Update on postmenopausal osteoporosis management.
One in two women has a fracture after the age of 50;1 most will be osteoporotic. Fracture incidence will probably increase as people live longer. After hip fracture there is 20% mortality within three months2 and increased disability, with >50% of people who previously walked unaided needing aids and >50% requiring help at home.3 Morbidity, disability and dependence increase progressively with ...
متن کاملManagement of postmenopausal osteoporosis.
Postmenopausal osteoporosis is associated with significant morbidity, mortality, reduction in quality of life, and increasing health care costs. It is estimated that 1.5 million women in the United States have one or more osteoporosis-related fractures annually. Fractures may occur at any site, but vertebral fractures are the most common. Longitudinal studies have demonstrated a decreased life ...
متن کاملUpdate on Denosumab Treatment in Postmenopausal Women with Osteoporosis
Denosumab, a fully human recombinant monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL), blocks binding of RANKL to the RANK receptor, found on the surface of osteoclasts and osteoclast precursors, resulting in decreased bone resorption. Subcutaneous denosumab administration once every 6 months increases bone mineral density at the lumbar spine, total hip, and/or ...
متن کاملUpdate on denosumab in the management of postmenopausal osteoporosis: patient preference and adherence
Patient adherence to many osteoporosis treatments, primarily bisphosphonates, is generally poor, thus leading to a significant reduction in antifracture efficacy. Patient perceptions about the necessity of the prescribed medication to treat osteoporosis and the concerns about the potential adverse effects are important and potentially modifiable determinants of adherence, in addition to other f...
متن کاملIbandronate in the Management of postmenopausal Osteoporosis
Oral daily and weekly bisphosphonates were considered, for several years, as the mainstay for the treatment of postmenopausal osteoporosis. However, the inconvenience of frequent dosing is known to negatively affect adherence to therapy in the long-term, hence outcomes. This has prompted the development of convenient oral bisphosphonate regimens that feature simple, less frequent dosing schedul...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Medicine
سال: 2007
ISSN: 1470-2118,1473-4893
DOI: 10.7861/clinmedicine.7-1-48